Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 2Warts 1Neutropenia 1Lymphoma, Non-Hodgkin 1Leukopenia 1Leukemia, Myeloid, Acute 1Infections 1Immunologic Deficiency Syndromes 1Hodgkin Disease 1Hematologic Neoplasms 1Agammaglobulinemia 1Acquired Immunodeficiency Syndrome 1

Interventions

Trimethoprim, Sulfamethoxazole Drug Combination 4gamma-Globulins 3Ciprofloxacin 3Immunoglobulins, Intravenous 2Amoxicillin-Potassium Clavulanate Combination 2talquetamab 1plerixafor 1idecabtagene vicleucel 1anifrolumab 1Wearable Electronic Devices 1Vital Signs 1Procalcitonin 1Plastic Surgery Procedures 1Immunoglobulins 1Fish Oils 1Ethanol 1Enteral Nutrition 1Dietary Supplements 1Cystectomy 1Control Groups 1Clavulanic Acid 1Amoxicillin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Infections × plerixafor × Clear all
NCT00967785 2026-05-22

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
20 enrolled

Agammaglobulinemia, Immunologic Deficiency Syndromes, Infections, Leukopenia, Neutropenia, Warts

Data powered by HemOnc (CC BY 4.0) Colophon âš¡